GlaxoSmithKline (GSK) Rating Reiterated by Kepler Capital Markets

Kepler Capital Markets restated their reduce rating on shares of GlaxoSmithKline (LON:GSK) in a report issued on Monday morning. The firm currently has a GBX 1,340 ($18.79) price objective on the stock.

Several other brokerages also recently commented on GSK. Deutsche Bank increased their price objective on GlaxoSmithKline from GBX 1,380 ($19.35) to GBX 1,440 ($20.19) and gave the stock a hold rating in a research note on Thursday, January 11th. set a GBX 1,925 ($26.99) price objective on GlaxoSmithKline and gave the stock a buy rating in a research note on Thursday, October 26th. Morgan Stanley lowered their price objective on GlaxoSmithKline from GBX 1,450 ($20.33) to GBX 1,400 ($19.63) and set an underweight rating for the company in a research note on Friday, December 1st. Berenberg Bank lowered their price objective on GlaxoSmithKline from GBX 1,835 ($25.73) to GBX 1,760 ($24.68) and set a buy rating for the company in a research note on Thursday, November 2nd. Finally, Goldman Sachs Group set a GBX 1,775 ($24.89) price objective on GlaxoSmithKline and gave the stock a buy rating in a research note on Friday, October 27th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of Hold and an average price target of GBX 1,542.95 ($21.63).

GlaxoSmithKline (LON GSK) opened at GBX 1,303.80 ($18.28) on Monday. The stock has a market capitalization of $64,640.00 and a P/E ratio of 4,205.81. GlaxoSmithKline has a fifty-two week low of GBX 1,235.20 ($17.32) and a fifty-two week high of GBX 1,724.50 ($24.18).

GlaxoSmithKline (LON:GSK) last announced its quarterly earnings results on Wednesday, February 7th. The company reported GBX 111.80 ($1.57) earnings per share (EPS) for the quarter, topping the consensus estimate of GBX 110.90 ($1.55) by GBX 0.90 ($0.01). The business had revenue of GBX 763.90 billion for the quarter. GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%.

In related news, insider Patrick Vallance sold 20,000 shares of the stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($18.37), for a total transaction of £262,000 ($367,358.38). Also, insider Sir Roy Anderson purchased 562 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were acquired at an average cost of GBX 1,278 ($17.92) per share, with a total value of £7,182.36 ($10,070.61). Insiders have purchased 581 shares of company stock valued at $743,284 over the last ninety days.

WARNING: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2018/02/09/glaxosmithkline-gsk-rating-reiterated-by-kepler-capital-markets.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit